Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients — Vicenç Ruiz de Porras (2019) | RDL Network
Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients
Article 2019 en
Authors
VP
Vicenç Ruiz de Porras
SB
Sara Bystrup
SH
Sara Cabrero-de las Heras
Abstract
1 min read
In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease.
Marco Erreni, Imran Siddiqui, Giulia Marelli, Fabio Grizzi, Paolo Bianchi, Diego Morone, Federica Marchesi, Giuseppe Celesti, Samantha Pesce, Andrea Doni, Cristiano Rumio, Massimo Roncalli, Luigi Laghi, Alberto Mantovani, Paola Allavena
Discussion(0)
No comments yet. Be the first to comment.